Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Semagacestat for Alzheimer's Disease

2,042 views

Published on

A review of a drug, Semagacestat, for the treatment of Alzheimer's Disease, that did not get approved by the FDA due increased side effects.

Published in: Health & Medicine
  • Be the first to comment

Semagacestat for Alzheimer's Disease

  1. 1. Termination of a Phase 3 Trial of Semagacestat for the Treatment of Alzheimer's Disease Rod Bugawan November 14, 2013 Lipscomb University College of Pharmacy
  2. 2. Learning Objectives • Describe Alzheimer’s Disease (AD) and recognize the risk factors • Describe the pathophysiology of AD • Recall the currently approved drug treatments • Describe semagacestat’s mechanism of action • Explain semagacestat’s role in therapy
  3. 3. What is Alzheimer’s Disease • Alios Alzheimer – 1906 • Not a normal part of aging • Irreversible, progressive brain disease: – Slowly destroys memory and thinking skills – Disorientation and ability to reason – Death • Risk factors: old age, family history, genetics (APOE-e4) http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics
  4. 4. Epidemiology and Costs • More than 5 million American are living with Alzheimer’s Disease (AD). 6th leading cause of death in the United States (US) • 1 out of every 3 Seniors in the US die from AD or other dementia • $203 Billion for 2013, $1.2 trillion by 2050 • In 2012, 15.4 million caregivers provided more than 17.5 billion hours of unpaid care valued at $216 billion http://www.alz.org/alzheimers_disease_facts_and_figures.asp
  5. 5. Change in number of deaths (2000-2010) http://www.alz.org/alzheimers_disease_facts_and_figures.asp
  6. 6. Learning Objectives • Describe Alzheimer’s Disease (AD) and recognize the risk factors • Describe the pathophysiology of AD • Recall the currently approved drug treatments • Describe semagacestat’s mechanism of action • Explain semagacestat’s role in therapy
  7. 7. Pathophysiology • Amyloid-beta plaques • Neurofibrillary tangles • Neuronal degradation https://neurowiki2012.wikispaces.com/Down+Syndrome
  8. 8. Pathophysiology • Schematic depiction of the process of amyloid-beta (AB) protein plaque formation. (National Institute on Aging) APP Amyloid Precursor Protein Beta and Gamma Secretase Aβ protein plaques in cortex and hippocampus https://neurowiki2012.wikispaces.com/Down+Syndrome
  9. 9. Learning Objectives • Describe Alzheimer’s Disease (AD) and recognize the risk factors • Describe the pathophysiology of AD • Recall the currently approved drug treatments • Describe semagacestat’s mechanism of action • Explain semagacestat’s role in therapy
  10. 10. Current FDA approved drugs • Cholinesterase inhibitors for mild to moderate AD – Work by stopping the breakdown of the acetylcholine, a neurotansmitter needed for communication – Donepazil, galantamine, rivastigmine, tacrine • N-methyl-D-aspartate (NMDA) receptor antagonists for moderate to severe AD – Brains most prominent excitatory neurotransmitter – Works by regulating excess glutamate caused by AD, slowing down neuronal damage – Memantine http://www.alz.org/alzheimers_disease_standard_prescriptions.asp
  11. 11. Learning Objectives • Describe Alzheimer’s Disease (AD) and recognize the risk factors • Describe the pathophysiology of AD • Recall the currently approved drug treatments • Describe semagacestat’s mechanism of action • Explain semagacestat’s role in therapy
  12. 12. Semagacestat’s Mechanism of Acation Schematic depiction of the process of amyloid-beta (Aβ) protein plaque formation (National Institute on Aging) APP Amyloid Precursor Protein Beta and Gamma Secretase Aβ protein plaques in cortex and hippocampus https://neurowiki2012.wikispaces.com/Down+Syndrome
  13. 13. Study Objective • Will semagacestat slow the progression of AD compared to placebo?
  14. 14. Study Design • Phase 3, multicenter, randomized, parallel, double-blind, placebo-controlled trial • 1537 patients with mild to moderate AD • 100 mg or 140 mg of semgacestat, or placebo in a 1:1:1 ratio • Outcome: changes in cognition and functioning based on assessment scales Doody RS et al: A Phase 3 Trial of Semagacestat for Treatment of Alzheimer’s Disease. N Engl J Med 2013 369(4)
  15. 15. Methods - Assignment • Screened 2009 patients, 1537 went randomization • Randomized by site (clinic location) and mild to moderate AD • Inclusion criteria – 55 years or older with mild to moderate AD without depression – Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within the past year with no findings inconsistent with a diagnosis of AD – Female must be without menstruation 12 consecutive months or have ovaries removed Doody RS et al.
  16. 16. Methods - Assignment • Exclusion criteria – Not capable of swallowing whole oral medication – Has serious or unstable illness – Does not have reliable caregiver – Chronic alcohol or drug abuse in past 5 years • 148 study locations globally Doody RS et al.
  17. 17. Methods - Protocol • Study drug, Semagacestat 100 mg or 140 mg, or placebo is dosed once a day for 76 weeks – No more than once daily because of inhibtion of Notch • Titrate from 60 mg starting dose to assigned dose to minimize adverse events (AEs) • 20 scheduled clinic visits Doody RS et al.
  18. 18. Methods - Assessment • Coprimary outcomes in 76 weeks – Alzheimer’s Disease Assessment Scale for Cognition (ADAS-cog) – Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL) • Compare changes of scores from baseline to endpoint Doody RS et al.
  19. 19. Methods - Assessment • Secondary outcomes in 76 weeks – Clinical Dementia Rating –Sum of Boxes (CDR-SB) – Mini-mental State Examination (MMSE) – Neuropsychiatric Inventory (NPI) – Resource Utilization Dementia (RUD-Lite)…. • Subset of patients – Cerebral Spinal Fluid levels (CSF) of Aβ – CSF for tau – Imaging studies Doody RS et al.
  20. 20. Doody RS et al.
  21. 21. Statistical Analysis • Interim safety analysis after 50% patients completed 12 months or dropped out – Treatment worse than control (P < 0.05) – Conduct futility analysis, recommend to stop trial • Mixed model repeated-measures analysis to compare model-adjusted least-squares means at 76 weeks • All analysis Intent-to-treat (ITT) Doody RS et al.
  22. 22. Statistical Analysis • Baseline Characteristics – Categorical variables: Fisher’s Exact or Chi-square test – Continuous variables: Analysis of Variance (ANOVA) • Safety analysis based on ITT – Summary listing of adverse events – Fisher’s exact test used for pairwise comparisons Doody RS et al.
  23. 23. Results – Baseline Characteristics Doody RS et al.
  24. 24. Results - Mean Change From Baseline Cognition score Daily Living Score Doody RS et al.
  25. 25. Results – Safety and Adverse Events • Lost weight in drug group, placebo gained weight (P < 0.001) -1.5 +/- 4.4 kg in 100mg Semagacestat -1.6 +/- 4.7 kg in 140 mg Semagacestat 0.4 +/- 3.9 kg in placebo • Small increase from basline in QT interval for the treatment groups vs placebo (p < 0.001) • AEs more common with semagacestat groups More cancers, skin and subcutaneous tissue disorders (P < 0.001) Doody RS et al.
  26. 26. Results – Safety and Adverse Events • Indirect evidence of Fancioni’s syndrome • Hepatocellulary injury, increase in cholesterol levels, decrease in direct bilirubin, reduction in IgG • Rate of serious AEs higher in treatment group (P < 0.001) – 24% in 100 mg semagacestat group – 25% in 140 mg semagacestat group – 14% in placebo • More deaths (9, 14, 6), P = 0.25 Doody RS et al.
  27. 27. Learning Objectives • Describe Alzheimer’s Disease (AD) and recognize the risk factors • Describe the pathophysiology of AD • Recall the currently approved drug treatments • Describe semagacestat’s mechanism of action • Explain semagacestat’s role in therapy
  28. 28. Authors’ Conclusion on Semagacestat • • • • No benefit for treatment of mild-to-moderate AD Associated with dose related clinical worsening Study stopped after futility analysis More adverse events and serious adverse events Doody RS et al.
  29. 29. Theories on Clinical worsening • Notch receptors impacted, is semagacestat more selective for Notch that APP? • Lack of significant reduction in Aβ in CSF? • Other inhibitory substrates? Doody RS et al.
  30. 30. Application • No current trials with semagacestat • 40 open trials for AD that are recruiting http://www.clinicaltrials.gov/ct2/results?term=alzheimer%27s+disease&recr=Open&no_unk=Y • Disease treatment pipeline – – – – – – Amyloid Beta (Aβ), plaques ---- semagacestat target Tau protein, neurofibrillary tangles Improving synaptic transmission Oxidative stress and inflammatory pathways Prevent AD Looking upstream, Aβ plaques can be detected 20 years before symptoms http://www.pmlive.com/pharma_news/alzheimers_disease_pipeline_takes_multiple_hits_493398
  31. 31. Questions http://www.alz.org/braintour/plaques_tangles.asp

×